These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18182889)

  • 1. Severe low turnover osteoporosis.
    Pietrogrande L
    Aging Clin Exp Res; 2007 Aug; 19(4 Suppl):26-9. PubMed ID: 18182889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vertebral body fracture--or what?].
    Wepner U
    MMW Fortschr Med; 2007 Nov; 149(45):18. PubMed ID: 18050592
    [No Abstract]   [Full Text] [Related]  

  • 5. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
    Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
    Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment.
    Resmini G; Iolascon G
    Aging Clin Exp Res; 2007 Aug; 19(4 Suppl):30-1. PubMed ID: 18182890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
    J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
    Fan G; Zhao Q; Lu P; Chen H; Tan W; Guo W; Liu C; Liu J
    Medicine (Baltimore); 2020 Apr; 99(15):e18964. PubMed ID: 32282692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
    Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
    Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
    Ulivieri FM
    Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of osteoporosis with PTH].
    Takeuchi Y
    Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anabolic therapy for osteoporosis.
    Bilezikian JP
    Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis.
    Keaveny TM; Donley DW; Hoffmann PF; Mitlak BH; Glass EV; San Martin JA
    J Bone Miner Res; 2007 Jan; 22(1):149-57. PubMed ID: 17042738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
    Endo I; Matsumoto T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
    [No Abstract]   [Full Text] [Related]  

  • 15. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures.
    Righetti M; Wach J; Desmarchelier R; Coury F
    Joint Bone Spine; 2018 May; 85(3):365-367. PubMed ID: 29246529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.
    Shen Y; Gray DL; Martinez DS
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):193-206. PubMed ID: 28131133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis GN; Efstathiadou Z; Kita M; Avramidis A
    Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing osteoporosis-related fractures: an overview.
    Gass M; Dawson-Hughes B
    Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.